ICAM1 and atherosclerosis: In a previous study by Wan et al. [49], the authors used the NLRP3 silencing technology to block the activation of the NLRP3 inflammasome and downregulate ICAM-1 and VCAM-1 in the intima, thus attenuating atherosclerosis and stabilizing atherosclerotic plaques in a diabetic atherosclerosis in vivo model.